Brain Disorders: Bridging Molecular Insights and Innovative Therapies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 2516

Editors


E-Mail Website
Guest Editor
Department of Neurosurgery and Neurooncology, Medical University of Lodz, Barlicki University Hospital, Lodz, Poland
Interests: bral ischemia; computational fluid dynamics; neurovascular compression syndromes; biomarkers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Neurosurgery and Neurooncology, Medical University of Lodz, Barlicki University Hospital, Lodz, Poland
Interests: neurosurgery; neuro-oncology; cancer-predisposing syndrome; CMMRD
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Brain disorders represent a significant challenge for modern medicine, spanning a wide range of conditions including cerebrovascular diseases and neuro-oncological disorders, some of which develop in the course of cancer-predisposing syndromes. Advances in neurosurgery, neuro-oncology, and vascular neurosurgery have opened new perspectives for treating complex entities such as aneurysms, gliomas, and other intracranial pathologies.

Recent progress in molecular biology, genomics, and advanced neuroimaging has deepened our understanding of disease mechanisms, from the molecular pathways driving tumor growth to the genetic alterations underlying cancer-predisposing syndromes such as neurofibromatosis and CMMRD. These insights have fostered the development of innovations in surgical techniques, targeted therapies, and personalized treatment strategies.

The aim of this Special Issue is to connect fundamental molecular discoveries with clinical applications, highlighting translational research that can improve diagnosis, treatment, and outcomes in patients with brain disorders. We invite submissions that cover topics including, but not limited to, the following:

  • Molecular characterization and novel therapies for gliomas and other brain tumors;
  • Genetic syndromes predisposing individuals to brain tumors, including CMMRD;
  • Translational research bridging basic science and clinical neurosurgery.

We welcome original research articles, clinical studies, and comprehensive reviews that will contribute to advancing the field from molecular mechanisms to innovative therapies.

Dr. Karol Wiśniewski
Dr. Bartosz Szmyd
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurosurgery
  • neuro-oncology
  • glioma
  • innovations
  • cancer predisposing syndrome
  • neurofibromatosis
  • CMMRD

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1525 KB  
Review
Intranasal Drug Delivery in Neuropharmacology: Advances in Brain-Targeted Therapies and Bioethical Challenges
by Simona Irina Damian, Sofia Mihaela David, Marcela Nour, Gabriela Liliana Halitchi, Sorina Alexandra Ciurlea, Alina Stefanache, Olga-Odetta Duma, Gabriela Calin and Doina Spaiuc
Biomedicines 2026, 14(3), 571; https://doi.org/10.3390/biomedicines14030571 - 2 Mar 2026
Cited by 1 | Viewed by 2123
Abstract
Intranasal drug delivery represents a transformative “backdoor” to the brain, bypassing the blood–brain barrier (BBB) that bars 98% of small molecules and nearly all large biopharmaceuticals. By harnessing the unique anatomy of the olfactory and trigeminal nerves, therapeutics can travel directly from the [...] Read more.
Intranasal drug delivery represents a transformative “backdoor” to the brain, bypassing the blood–brain barrier (BBB) that bars 98% of small molecules and nearly all large biopharmaceuticals. By harnessing the unique anatomy of the olfactory and trigeminal nerves, therapeutics can travel directly from the nasal cavity to the central nervous system, achieving therapeutic concentrations without the systemic toxicity of traditional routes. Clinical and preclinical evidence highlight the efficacy of intranasal insulin (INI) in treating Alzheimer’s disease (AD) and delirium, with studies showing significant improvements in cognitive scores and reduced hospital stays (7.9 vs. 12.9 days; p = 0.014). Additionally, other peptides can be administered intranasally like oxytocin, neuropeptide Y, and novel metabolic modulators for neuroprotection and affective disorders (AD, autism, Down syndrome). Despite these promises, critical translational gaps remain, including anatomical differences between macrosmatic rodents and microsmatic humans, and significant sex-based dosing dimorphism. The ease of intranasal administration introduces profound bioethical dilemmas regarding neuroenhancement, authenticity, and informed consent in vulnerable populations. The current literature concludes that realizing the full potential of nose-to-brain (N2B) therapy requires a commitment to precision medicine, utilizing specialized delivery devices and objective biomarkers to ensure safe and equitable clinical application. Full article
(This article belongs to the Special Issue Brain Disorders: Bridging Molecular Insights and Innovative Therapies)
Show Figures

Figure 1

Back to TopTop